Bharat Biotech Ankleshwar wing to make Covaxin: Product availability from Q4 2021
Bharat Biotech has ramped up additional business volumes for the Covaxin covid-19 injections as the nation faces a severe scarcity of vaccines. Chiron Behring, a subsidy of Bharat Biotech in Ankleshwar, Gujarat, devices to yield 200 million doses of Covaxin per year in the GMP facilities that are already working for the production of vaccines based on Deactivated Vero Cell Platform Technology, under rigorous levels of GMP and biosafety.
The accumulation in industrial competences takes the volume of covaxin doses to up to 1 billion doses per year. The company raged up volumes at its own recognized campuses focused for business inactivated viral vaccines under the highest biosafety points.
Bharat Biotech had already deployed numerous production outlines at its Hyderabad and Bengaluru sites amid growing tests confronted by the nation and the extremely slowed speed of the nationwide vaccination drive in face of depleted vaccine stocks.